Summit Therapeutics PLC
$ 13.11
-4.06%
27 Jul - close price
- Market Cap 10,897,260,000 USD
- Current Price $ 13.11
- High / Low $ 14.23 / 13.10
- Stock P/E N/A
- Book Value 0.70
- EPS -1.11
- Next Earning Report 2026-10-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.02 %
- ROE -1.93 %
- 52 Week High 30.98
- 52 Week Low 12.55
About
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America, and Europe. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$28.69
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-23 | 2026-04-30 | 2026-02-23 | 2025-10-20 | 2025-08-11 | 2025-05-01 | 2025-02-24 | 2024-10-30 | 2024-08-06 | 2024-05-01 | 2024-02-20 | 2023-11-07 |
| Reported EPS | -0.28 | -0.1767 | -0.21 | -0.23 | -0.12 | -0.0677 | -0.06 | -0.06 | -0.07 | -0.05 | -0.04 | -0.03 |
| Estimated EPS | -0.26 | -0.1217 | -0.01 | -0.04 | -0.09 | -0.0682 | -0.06 | -0.05 | -0.05 | -0.05 | -0.05 | None |
| Surprise | -0.02 | -0.055 | -0.2 | -0.19 | -0.03 | 0.0005 | 0 | -0.01 | -0.02 | 0 | 0.01 | 0 |
| Surprise Percentage | -7.6923% | -45.1931% | -2000% | -475% | -33.3333% | 0.7331% | 0% | -20% | -40% | 0% | 20% | None% |
Next Quarterly Earnings
| Sep 2026 | |
|---|---|
| Reported Date | 2026-10-19 |
| Fiscal Date Ending | 2026-09-30 |
| Estimated EPS | -0.22 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SMMT
2026-07-27 13:40:05
Kuehn Law, PLLC is investigating officers and directors of Summit Therapeutics Inc. for potential breaches of fiduciary duties and self-dealing, which could lead to shareholder damages and corporate governance reforms. Long-term shareholders are encouraged to seek a free consultation to explore their rights. This investigation raises concerns about management integrity and investor protection at Summit Therapeutics.
2026-07-27 10:40:05
Summit Therapeutics (SMMT) has presented updated Phase III data for ivonescimab, a new PDUFA date, and a collaboration with Arcus Biosciences, yet its share price has declined in the short term. While a popular narrative suggests the company is 52% undervalued based on future cash flows from its broad pipeline, its current P/B ratio of 17.3x implies a rich valuation compared to industry peers. The article explores the tension between these valuation perspectives and highlights risks such as trial failures or dilutive funding.
2026-07-27 03:05:23
Summit Therapeutics Inc (SMMT) has an earnings forecast score of 7.67, ranking 277 out of 386 in its industry, with an average price target of $34.50, suggesting a significant upside. Analysts project the company's next quarter revenue to be $90.91 million and anticipate EPS of -$0.28, following a previous quarter's EPS of -$0.24. The consensus amongst 18 analysts is a "Buy" rating for SMMT stock.
2026-07-26 14:11:22
Summit Therapeutics (SMMT) reported a Q4 2025 non-GAAP EPS miss, highlighting its status as a pre-revenue clinical-stage biotechnology firm with substantial cash burn. Despite the miss, the FDA's acceptance of the Biologics License Application (BLA) for ivonescimab in NSCLC, with a PDUFA date of November 14, 2026, is a key catalyst. The company maintains a strong cash reserve of $713.4 million, providing a runway for its extensive Phase III pipeline, but future dilution remains a risk for investors as it navigates the path to commercialization.
2026-07-24 17:40:26
Summit Therapeutics Inc.'s average 12-month stock price target has been adjusted to $29.06, down from $29.84, based on estimates from 14 analysts. This new target suggests a potential upside of approximately 94% from its closing price on July 23. The consensus rating for SMMT remains a "Buy" among 17 analysts.
2026-07-24 15:40:26
Summit Therapeutics has disclosed a "going concern" risk due to insufficient cash and short-term investments to fund its operations for the next year. The company, despite raising $299.2 million through its ATM facility, expects continued operating losses and is exploring financing options. Summit Therapeutics also recently sold its ridinilazole asset for an upfront payment and potential future milestones and royalties.
